Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Impact of a Low Carbohydrate Breakfast on Glucose Control in Type 2 Diabetes

Condition:   Type2 Diabetes
Interventions:   Behavioral: Low Carbohydrate Breakfast;   Behavioral: Guidelines Breakfast
Sponsor:   University of British Columbia
Recruiting - verified November 2016

Experimental Changes in Children's Sleep Duration and Timing: Effect on Obesity and Type 2 Diabetes Risk

Conditions:   Type2 Diabetes;   Sleep
Interventions:   Behavioral: Sleep duration 90 min;   Behavioral: Sleep duration 45 min;   Behavioral: Sleep timing
Sponsor:   Temple University
Not yet recruiting - verified December 2016

Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise

Condition:   Insulin Resistance, Diabetes
Intervention:   Behavioral: exercise
Sponsor:   The Cleveland Clinic
Recruiting - verified November 2016

Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes

Condition:   Type2 Diabetes
Interventions:   Drug: evogliptin;   Drug: Linagliptin
Sponsor:   Dong-A ST Co., Ltd.
Recruiting - verified November 2016

Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

Condition:   Type 2 Diabetes
Interventions:   Drug: exenatide once weekly;   Drug: basal insulin
Sponsor:   AstraZeneca
Completed - verified November 2016

Blueberry Consumption and Type 2 Diabetes

Condition:   Type2 Diabetes
Interventions:   Other: Blueberry;   Other: Placebo
Sponsor:   Albany Research Institute, Inc.
Recruiting - verified November 2016

A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified November 2016

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR425899;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified December 2016

Glooko Enabled Remote Monitoring for Insulin-treated Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: Glooko's mobile application
Sponsor:   Glooko
Not yet recruiting - verified November 2016

Effect of a Nutrient Dense Plant Rich Diet on Glycemic Control in People With Type 2 Diabetes and Obesity

Condition:   Type 2 Diabetes Mellitus in Obese
Interventions:   Other: NDPR diet;   Other: USDA healthy eating diet
Sponsors:   Beth Israel Deaconess Medical Center;   Nutritarian Research Foundation
Not yet recruiting - verified November 2016

Study With Dapagliflozin

Condition:   Diabetes Mellitus Type 2
Intervention:  
Sponsor:   AstraZeneca
Not yet recruiting - verified November 2016

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

Conditions:   Type2 Diabetes;   Cardiovascular Diseases
Interventions:   Drug: Dapagliflozin;   Drug: Glimepiride
Sponsors:   University of Michigan;   AstraZeneca
Not yet recruiting - verified November 2016

Role of Gastrointestinal Microbes on Digestion of Resistant Starch and Tryptophan Availability to Humans

Condition:   Type II Diabetes
Interventions:   Dietary Supplement: Potato Starch (Bob's Red Mill);   Dietary Supplement: Pregelatinized Starch (Resource ThickenUp)
Sponsor:   Wayne State University
Not yet recruiting - verified November 2016

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   The University of Texas Health Science Center at San Antonio;   AstraZeneca
Not yet recruiting - verified December 2016

Real World Experience of Dapaglifozin in Type 2 Diabetes

Condition:   Type2 Diabetes
Intervention:  
Sponsor:   University of Malaya
Not yet recruiting - verified November 2016

Insulin Sensitivity, Glucose - and Fat Metabolism in Patients With Psoriasis

Conditions:   Insulin Sensitivity;   Metabolism Disorder
Intervention:   Other: Stabile Isotope tracers
Sponsor:   University Hospital, Gentofte, Copenhagen
Recruiting - verified November 2016

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified December 2016

A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin 287;   Drug: placebo;   Drug: insulin degludec;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified November 2016

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

Conditions:   Metabolism and Nutrition Disorder;   Obesity
Interventions:   Drug: Liraglutide 3.0 mg;   Drug: Placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified November 2016

diEtitiaNs Helping pAtieNts CarE for Diabetes (ENHANCED)

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: Coaching
Sponsors:   Minneapolis Heart Institute Foundation;   Academy of Nutrition and Dietetics
Enrolling by invitation - verified November 2016

Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis

Condition:   Endstage Renal Disease
Intervention:   Other: Sodium Propionate
Sponsor:   Azienda Sanitaria ASL Avellino 2
Not yet recruiting - verified November 2016

The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes

Conditions:   Type2 Diabetes;   NAFLD
Intervention:   Drug: Empagliflozin
Sponsor:   University of Malaya
Not yet recruiting - verified November 2016

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: metformin;   Drug: sulfonylurea;   Drug: meglitinides;   Drug: thiazolidinediones;   Drug: alpha-glucosidase inhibitors;   Drug: GLP1 Receptor Agonist;   Drug: Dipeptidyl peptidase-IV (DPP-IV) inhibitors;   Drug: Sodium-glucose transport-2 (SGLT-2) inhibitors
Sponsor:   Sanofi
Recruiting - verified December 2016

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Bexagliflozin;   Drug: Metformin;   Drug: Glimepiride;   Drug: Sitagliptin
Sponsor:   Theracos
Recruiting - verified November 2016

Chronotype of Patients With Type 2 Diabetes and Effect on Glycaemic Control

Condition:   Type2 Diabetes
Intervention:  
Sponsors:   University of Leicester;   University Hospitals, Leicester
Not yet recruiting - verified October 2016

A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY3209590;   Drug: Placebo;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified November 2016

A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Faster Aspart;   Drug: Insulin Aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified November 2016

Efficacy and Safety of Sotagliflozin Versus Placebo in Drug-naïve Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo
Sponsor:   Sanofi
Recruiting - verified November 2016

Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sotagliflozin (SAR439954);   Drug: Placebo;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified December 2016

A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/liraglutide;   Drug: Insulin degludec
Sponsor:   Novo Nordisk A/S
Recruiting - verified November 2016

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified December 2016

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Insulin degludec/insulin aspart;   Drug: Insulin glargine;   Drug: Insulin aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified November 2016

Using a Transcutaneous Electrical Auricular Stimulator to Harness the Cholinergic Anti-Inflammatory Pathway

Condition:   Healthy Volunteers
Interventions:   Device: Vagus Nerve Stimulation;   Device: Sham Vagus Nerve Stimulation
Sponsor:   Northwell Health
Completed - verified November 2016

The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Henrik Enghusen Poulsen;   University Hospital, Gentofte, Copenhagen;   University of Copenhagen
Recruiting - verified December 2016

Impact of Overfeeding and Following Exercise Training in Individuals With and Without Increased Risk of Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus;   Insulin Resistance;   Dyslipidemia
Interventions:   Dietary Supplement: High carbohydrate overfeeding;   Behavioral: Exercise;   Behavioral: Normal physical activity
Sponsors:   Rigshospitalet, Denmark;   Novo Nordisk A/S;   Augustinus Fonden
Recruiting - verified December 2016

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Condition:   Male Subjects With Type II Diabetes (T2DM)
Interventions:   Drug: AZD8601+Placebo (SAD);   Drug: AZD8601+Placebo;   Drug: Placebo+Placebo
Sponsors:   AstraZeneca;   PAREXEL International GmbH;   Spandauer Damm 130;   14050;   Berlin, Germany
Not yet recruiting - verified November 2016

Effectiveness of Self-care Rests on Knowledge, Self-care and Cardiometabolic Control of Adult Men With Diabetes Mellitus

Condition:   Diabetes Mellitus
Intervention:   Behavioral: self-care supported
Sponsor:   Universidade Estadual de Maringá
Recruiting - verified November 2016

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine (U300);   Drug: Insulin glargine;   Drug: Non-insulin antihyperglycemic drugs
Sponsor:   Sanofi
Recruiting - verified November 2016

ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2
Intervention:   Behavioral: Shared Decision Making
Sponsors:   AstraZeneca;   Brigham Women's Health
Recruiting - verified December 2016

Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified December 2016

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin
Sponsor:   Novo Nordisk A/S
Recruiting - verified December 2016

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified December 2016

JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: JARDIANCE 10mg;   Drug: JARDIANCE 25mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified November 2016

Diabetes Complication Control in Community Clinics (D4C) Trial

Conditions:   Diabetes;   Hypertension;   Dyslipidemia;   Cardiovascular Disease
Intervention:   Other: Protocol-based integrated care
Sponsors:   Tulane University;   Xiamen University
Recruiting - verified November 2016

Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: JNJ-64565111;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Suspended - verified November 2016

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Condition:   Hypertension
Intervention:   Drug: CS-3150
Sponsor:   Daiichi Sankyo Co., Ltd.
Recruiting - verified November 2016

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

Condition:   T2DM With NAFLD
Interventions:   Drug: AZD4076;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified November 2016

Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified December 2016

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified December 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: metformin;   Drug: pioglitazone
Sponsor:   Sanofi
Recruiting - verified November 2016

An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Exenatide;   Drug: Albiglutide
Sponsors:   GlaxoSmithKline;   Wake Forest Baptist Health
Recruiting - verified December 2016

A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Recruiting - verified December 2016

EndoBarrier in Obese Subjects With Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes;   Obesity
Intervention:   Device: EndoBarrier
Sponsor:   Medical University of Graz
Active, not recruiting - verified November 2016

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/insulin aspart;   Drug: biphasic insulin aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified November 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified November 2016

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified November 2016

Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Device: Auto-injector
Sponsor:   GlaxoSmithKline
Recruiting - verified November 2016

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo to stiagliptin;   Drug: Metformin;   Drug: Metformin XR;   Drug: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified November 2016

Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Tesofensine/Metoprolol;   Drug: Placebo
Sponsors:   Saniona;   Profil Institut für Stoffwechselforschung GmbH
Active, not recruiting - verified November 2016

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: Insulin degludec;   Drug: GLP-1 receptor agonist;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified November 2016

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

Condition:   Acute Kidney Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified December 2016

Acute Liver Injury in Patients on Dapagliflozin

Condition:   Acute Liver Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified December 2016

Complications of UTI in Patients on Dapagliflozin

Condition:   Severe Complications of Urinary Tract Infections
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified December 2016

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

Conditions:   Breast Cancer;   Bladder Cancer
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified December 2016

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Conditions:   Type2 Diabetes Mellitus;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Placebo for Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo for Saxagliptin
Sponsor:   AstraZeneca
Recruiting - verified December 2016

CMR in Type 2 Diabetes Mellitus Patients

Conditions:   Diabetes Mellitus, Type 2;   Heart Disease
Interventions:   Other: Cardiac Magnetic Resonance Imaging (CMR);   Other: Echocardiography;   Other: Bood samples
Sponsor:   Slagelse Hospital
Recruiting - verified November 2016

A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: DS-8500a 25 mg;   Drug: DS-8500a 75 mg;   Drug: placebo
Sponsors:   Daiichi Sankyo Co., Ltd.;   Mediscience Planning, Inc.
Completed - verified November 2016

Vaccine Efficacy in Diabetic and Elderly Patients

Condition:   Inflammation
Intervention:   Biological: Influenza Virus Vaccine
Sponsors:   Tulane University;   Louisiana Clinical and Translational Science Center
Recruiting - verified November 2016

A Phase2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: DS-8500a;   Drug: Sitagliptin;   Drug: placebo
Sponsor:   Daiichi Sankyo Co., Ltd.
Active, not recruiting - verified November 2016

A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Insulin Lispro
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified November 2016

Effect of Dapagliflozin on Inflammation and Endothelial Function

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsor:   Baylor College of Medicine
Recruiting - verified November 2016

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin degludec;   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Recruiting - verified December 2016

Initial Combination of Gemigliptin and Metformin on Microbiota Change

Condition:   Diabetes
Interventions:   Drug: gemigliptin/metformin;   Drug: glimepiride/metformin
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified November 2016

Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Placebo;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified November 2016

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Ipragliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified November 2016

Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified November 2016

Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction

Condition:   Diabetes
Interventions:   Dietary Supplement: Cambridge Weight Plan;   Other: Supervised Exercise Sessions
Sponsors:   University of Leicester;   University Hospitals, Leicester;   National Institute for Health Research, United Kingdom
Recruiting - verified November 2016

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified November 2016

Foxiga Korea Local Phase 4 Study

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dapagliflozin;   Drug: Glimepiride
Sponsor:   AstraZeneca
Recruiting - verified November 2016

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Met DR;   Drug: Met IR;   Drug: Placebo
Sponsor:   Elcelyx Therapeutics, Inc.
Completed - verified November 2016

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified November 2016

Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting

Condition:   Healthy
Interventions:   Other: Fasting;   Drug: Saline;   Drug: Pegvisomant
Sponsor:   University of Aarhus
Completed - verified November 2016

Probiotics in Diabesity: A Pilot Study

Conditions:   Diabetes;   Obesity
Interventions:   Dietary Supplement: Winclove 851 and 110;   Dietary Supplement: Placebo
Sponsor:   Medical University of Graz
Recruiting - verified November 2016

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified November 2016

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified November 2016

A Biobehavioral Model of Diabetes Risk in Chinese Immigrants

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Fox Chase Cancer Center
Recruiting - verified November 2016

Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death

Conditions:   Tissue and Organ Harvesting;   Liver Transplantation;   Brain Death
Intervention:   Procedure: Fibroscan
Sponsor:   University Hospital, Limoges
Recruiting - verified November 2016

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified November 2016

Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus

Conditions:   Type 2 Diabetes;   NAFLD;   Obesity;   Dyslipoproteinaemia;   Hypertension
Intervention:   Behavioral: dietary consulting and advise
Sponsors:   German Institute of Human Nutrition;   German Center for Diabetes Research;   California Walnut Corporation;   Institute for Cereal Processing GmbH/Institut für Getreideverarbeitung (IGV)
Recruiting - verified November 2016

Diabetes Nutrition Algorithm - Prediabetes

Conditions:   Prediabetes;   Diabetes Mellitus Type 2;   Obesity;   NAFLD;   Dyslipoproteinemia
Intervention:   Behavioral: dietary consulting
Sponsors:   German Institute of Human Nutrition;   German Diabetes Center
Recruiting - verified November 2016

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GLWL-01, Part A;   Drug: Placebo, Part A;   Drug: GLWL-01, Part B;   Drug: Placebo, Part B;   Drug: GLWL-01, Part C;   Drug: Placebo, Part C
Sponsor:   GLWL Research Inc.
Recruiting - verified November 2016

Effects of Linagliptin on Endothelial Function

Conditions:   Type 2 Diabetes;   Coronary Artery Disease
Interventions:   Drug: Linagliptin;   Drug: Placebo
Sponsor:   Medical University of Graz
Active, not recruiting - verified November 2016

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified November 2016

Effect of Soft Fruit on Postprandial Blood Glucose

Condition:   Type 2 Diabetes
Interventions:   Dietary Supplement: Blackcurrants with polycal OGTT;   Dietary Supplement: Greencurrants with polycal OGTT;   Dietary Supplement: Blackcurrants with glucose OGTT;   Dietary Supplement: Sugar matched water with polycal OGTT
Sponsor:   University of Aberdeen
Recruiting - verified December 2016

Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

Condition:   Coronary Artery Disease
Interventions:   Drug: Cilostazol;   Drug: Aspirin
Sponsor:   Seoul National University Bundang Hospital
Completed - verified November 2016

Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Completed - verified December 2016

Triple Combination of Metformin, Sitagliptin and Thiazolidinedione in Drug-naïve Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Intervention:   Drug: Thiazolidinedione
Sponsor:   Seoul National University Bundang Hospital
Recruiting - verified November 2016

Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide;   Drug: Insulin Glargine and Insulin Lispro
Sponsors:   GlaxoSmithKline;   PPD
Active, not recruiting - verified November 2016

Changes in Intrahepatic Lipids With Exercise

Condition:   Obese
Interventions:   Other: high intensity exercise;   Other: continuous moderate exercise
Sponsor:   University of Missouri-Columbia
Recruiting - verified December 2016

Omega-3 Fatty Acids Supplementation and Atherothrombotic Biomarkers in Type 2 Diabetes and Cardiovascular Disease.

Conditions:   Type 2 Diabetes;   Cardiovascular Diseases
Intervention:   Dietary Supplement: Omega-3 PUFA
Sponsors:   Jagiellonian University;   National Science Centre, Poland
Completed - verified November 2016

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus

Conditions:   Type 2 Diabetes;   Hypertension
Intervention:   Drug: amlodipine, hydralazine, terazosin or hydrochlorothiazide
Sponsor:   Tulane University Health Sciences Center
Recruiting - verified December 2016

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   Hypertensive Disease
Intervention:   Drug: Liraglutide or Placebo
Sponsors:   Tulane University Health Sciences Center;   Novo Nordisk A/S
Completed - verified December 2016

Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   David Grant U.S. Air Force Medical Center
Withdrawn - verified December 2016

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed - verified November 2016

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified November 2016

Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified November 2016

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Albuminuria
Interventions:   Drug: Placebo;   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified November 2016

Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis

Condition:   Non-Insulin Dependent Diabetes Mellitus
Intervention:   Dietary Supplement: magnesium lactate
Sponsors:   George Washington University;   Nadia Zghoul, PhD, Dept of Clinical Research;   Dasman Diabetes Institute
Completed - verified November 2016

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified November 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified November 2016

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Video Games for Obesity and Diabetes Prevention-Diab & Nano

Conditions:   Obesity;   Type 2 Diabetes
Intervention:   Behavioral: G4H-Diab-Nano
Sponsor:   Baylor College of Medicine
Recruiting - verified November 2016

Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified November 2016

Diabetes Nutrition Algorithms - Sugars: Galactose- and Fiber-induced Metabolic Improvement in the Dietetic Treatment of Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Dietary Supplement: Dietary supplement (4 arms, 2 active, 2 placebo)
Sponsors:   German Institute of Human Nutrition;   Firma Rettenmeier & Söhne (Company);   German Center for Diabetes Research
Recruiting - verified November 2016

Better Diabetes Control, Quality - Educate to Achieve Compliance.

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified November 2016

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified November 2016

Cardiovascular Inflammation Reduction Trial

Condition:   Cardiovascular Disease
Interventions:   Drug: Methotrexate;   Drug: Placebo
Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2016

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified November 2016

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Glycemic Rescue 1;   Drug: Glycemic Rescue 2;   Biological: Glycemic Rescue 3
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified November 2016

Risk Factors for Low Lymphocyte Count in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Bristol-Myers Squibb
Completed - verified November 2016

Study of Oral Anthocyanins on Insulin Resistance

Condition:   Type 2 Diabetes
Intervention:   Dietary Supplement: Mirtoselect
Sponsor:   University of Aberdeen
Recruiting - verified December 2016

A Biological Atlas of Severe Obesity (Biological Tissue Collection)

Conditions:   Obesity;   Glucose Intolerance;   Diabetes
Intervention:  
Sponsor:   University Hospital, Lille
Recruiting - verified November 2016

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2016

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GSK1292263;   Drug: GSK1292263 matching placebo;   Drug: Sitagliptin
Sponsor:   GlaxoSmithKline
Completed - verified November 2016

A Clinical Trial to Assess the Safety of Oral SRT2104 and Its Effects on Vascular Dysfunction in Otherwise Healthy Cigarette Smokers and Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: SRT2104
Sponsors:   Sirtris, a GSK Company;   GlaxoSmithKline
Completed - verified November 2016

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified November 2016

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GSK1292263;   Drug: GSK1292263 matching placebo;   Drug: Sitagliptin
Sponsor:   GlaxoSmithKline
Completed - verified December 2016

A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Biological: albiglutide
Sponsor:   GlaxoSmithKline
Completed - verified November 2016

A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Taiwan

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Completed - verified November 2016

A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Malaysia

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Intervention:   Other: No treatment given
Sponsor:   Novo Nordisk A/S
Completed - verified November 2016

Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: insulin detemir
Sponsor:   Novo Nordisk A/S
Completed - verified November 2016

Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir®

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: insulin detemir
Sponsor:   Novo Nordisk A/S
Completed - verified November 2016

Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin detemir;   Drug: insulin NPH
Sponsor:   Novo Nordisk A/S
Completed - verified November 2016

Exercise and Cardiovascular Control During Upright Tilt in Older Adults With Type 2 Diabetes

Conditions:   Cardiovascular;   Diabetic
Interventions:   Behavioral: Aerobic Exercise and Strength Exercise;   Behavioral: Strength training
Sponsors:   University of British Columbia;   Canadian Institutes of Health Research (CIHR)
Completed - verified November 2016

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Human Insulin Inhalation Powder;   Drug: Insulin Glargine
Sponsors:   Eli Lilly and Company;   Alkermes, Inc.
Completed - verified November 2016

A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Human Insulin Inhalation Powder;   Drug: Insulin
Sponsor:   Eli Lilly and Company
Completed - verified November 2016

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Human Insulin Inhalation Powder;   Drug: Injectable insulin
Sponsors:   Eli Lilly and Company;   Alkermes, Inc.
Completed - verified November 2016

Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)

Conditions:   Kidney Transplant;   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Cyclosporin;   Drug: Tacrolimus;   Behavioral: 'Diabetes Education / Management'
Sponsor:   Stanford University
Completed - verified November 2016

Safety and Efficacy of Inhaled Insulin in Patients With Diabetes and Asthma or COPD

Conditions:   Diabetes Mellitus;   Asthma;   Pulmonary Disease, Chronic Obstructive
Interventions:   Drug: Human Insulin Inhalation Powder;   Drug: injected insulin
Sponsors:   Eli Lilly and Company;   Alkermes, Inc.
Completed - verified November 2016